The Biomarker Market was valued at USD 47.35 billion in 2021 and is expected to register a CAGR of 13.76% during the forecast period.
The COVID-19 pandemic led to a lot of disruption in almost every sector. The healthcare sector also faced a similar unprecedented impact in its domain. However, this is not the case in the biomarker market, as biomarkers are playing a crucial role in the development of therapies for chronic cases, where government and pharmaceutical industries will spend a lot, hampering the market growth. There are various research has been conducted, and biomarkers are found to play a critical role in the diagnosis and treatment of COVID-19. The article in Journal PLOS One titled ‘Laboratory biomarkers of COVID-19 disease severity and outcome: Findings from a developing country’ published in March 2021, suggests that timely identification of biomarkers of COVID-19 disease severity and mortality would help to provide targeted intervention and patient management. Moreover, many organizations have launched biomarker products to detect and diagnose COVID-19. In November 2020, blinkTEST, a handheld biosensor device that can detect COVID-19 and other disease biomarkers in saliva, will be released by Blink Science, new biotechnology and medical device firm. The stress of awaiting test results can be detrimental to one's health and the global economy. Most current point-of-care (POC) testing devices and those that have received Emergency Use Authorization (EUA) provide results in more than 20-30 minutes.
Furthermore, the high prevalence of cancer and cardiac problems and biomarker advancements are the major factors attributed to biomarker market drivers. The spike in cancer cases globally increased the uses with advances in technology. There were 18 million cases worldwide, according to the WCRF (World Cancer Research Fund International). In addition, governments and pharmaceutical companies are concerned about the global burden of cancer prevention and cure.
According to the World Health Organization, each year, an estimated 17.9 million people die due to cardiovascular diseases worldwide. This represents 35% of global deaths. Moreover, heart attacks and stroke account for 85 percent of all deaths related to cardiovascular disease. Ischemic heart disease (IHD) is also a leading cause of death worldwide, according to an article published in the Cureus Journal of Medical Science in July 2020. Ischemic heart disease affects around 126 million individuals (1,655 per 100,000) globally, approximately 1.72% of the world’s population. The global prevalence of ischemic heart disease is expected to exceed 1,845 per 100,000 by 2030. Also, the burden of cancer continues to grow globally, exerting tremendous physical, emotional, and financial strain on individuals, families, communities, and health systems; according to the Global Cancer Observatory (Globocan) 2020, the estimated prevalent cancer cases all over the globe in 2020 account for 15,545,712. Out of which Asia has 6,108,288 of the general issues, Europe accounts for 3,455,761; North America has 2,166,628, Latin America and the Caribbean has 1,023,898, and Africa has 4.5% 615,015 of the total prevalent cases.
Thus, with the increasing prevalence of life-threatening diseases, the biomarker market is expected to show lucrative growth over the forecast period.
The rising incidence of different types of cancers is expected to boost demand. For instance, according to Globocan 2020, 1,414,259 new prostate cancer cases were detected in 2020. The high incidence of this cancer type is increasing the demand for biomarkers. One of the most common biomarkers for prostate cancer is prostate-specific antigen (PSA). The PSA test, which detects abnormally high blood levels of PSA, has been used for decades to screen for prostate cancer and potentially diagnose it early.
Additionally, according to Globocan 2020, 2,261,419 new breast cancer cases were detected in 2020. Breast cancer biomarkers, such as estrogen receptor (ER), progesterone receptor, and HER2, are available to see this type of cancer. However, additional tools are required to facilitate the clinical decision-making processes, especially for the optimal treatment of early hormone receptor-positive breast cancer. Some emerging biomarkers include Ki67, Cyclin E, Cyclin D1, and ERβ. The rise in the number of breast cancer cases across the world is expected to boost the demand for biomarkers for its fast detection.
Many companies are involved in the launch of new tests or programs for cancer detection by using biomarkers. For instance, in April 2021, Amgen launched its biomarker assist program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) access biomarker testing. Through this program, eligible patients can save on biomarker testing. Initiatives such as these can boost the market growth.
Additionally, in December 2020, Personalis, Inc. launched its proprietary Neoantigen Presentation Score (NEOPS), a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines analysis from Personalis’ tumor neoantigen prediction tool SHERPA with mechanisms of immune evasion to predict response to cancer therapy better. This is expected to boost the market growth.
Furthermore, the government and pharmaceutical companies are spending a lot on the advancement in the therapy, which eventually leads to the growth of the biomarker market globally. Introducing new cancer biomarkers will increase the market size of biomarkers in the forecast period. Breast and lung cancer dominate the cancer biomarker market, and these cases will increase in the coming years. Thus, the biomarker revenue will also rise in the forecast period.
North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. The number of USFDA-approved drug labels containing information on molecular biomarkers has increased dramatically over the last decade.
Moreover, the increasing burden of chronic diseases in the United States generates the demand for biomarkers. According to the National Center for Chronic Disease Prevention and Health Promotion’s Article titled Chronic Diseases in America, updated in January 2021, 6 out of the ten adults in the United States have a chronic disease, and 4 in the ten adults have two or more chronic conditions. The biomarker is used for the early diagnosis and treatment of chronic diseases.
Also, the government is focusing on research and the development of biomarkers. For instance, the National Institute of Neurological Disorders and Stroke’s Article titled ‘focus on Biomarker Research,’ updated in July 2021, the NINDS Biomarker Program supports rigorous biomarker development and validation to improve the quality and efficiency of neurotherapeutic clinical research.
Also, according to the Global Cancer Observatory (Globocan) 2020, the United States has the second largest number of prevalent cases of cancer in the world. The real prevalent issues of all ages account for 1,932,997 in 2020. As biomarkers have broad applications in therapy for the diagnosis and treatment of cancer, the demand for them is expected to increase in the country.
The number of products and programs launched by the market players also drives the market's growth in the region. For instance, in April 2021, Amgen launched the Biomarker Assist program to improve the accessibility of biomarker testing for metastatic (stage IV) non-small cell lung cancer (NSCLC) patients. Biomarker testing at the time of diagnosis is an essential first step in ensuring that patients receive the best treatment possible. The eligible patient can save money on biomarker testing with the help of Biomarker Assist.
Thus, for the reasons above, the biomarker market is expected to show lucrative growth in the North American region over the forecast period.
The biomarker market is moderately competitive. The majority of the market share is possessed by Abbott Laboratories Inc., Johnson & Johnson, Roche Diagnostics, Bio-Rad Laboratories, Epigenomics AG, and Qiagen. The growth of this market majorly depends on the advancement in technology and investment in R&D. Today, most pharmaceutical companies are investing in R&D, and governments are also spending a considerable sum of money on the progress of technology.
This product will be delivered within 2 business days.
The COVID-19 pandemic led to a lot of disruption in almost every sector. The healthcare sector also faced a similar unprecedented impact in its domain. However, this is not the case in the biomarker market, as biomarkers are playing a crucial role in the development of therapies for chronic cases, where government and pharmaceutical industries will spend a lot, hampering the market growth. There are various research has been conducted, and biomarkers are found to play a critical role in the diagnosis and treatment of COVID-19. The article in Journal PLOS One titled ‘Laboratory biomarkers of COVID-19 disease severity and outcome: Findings from a developing country’ published in March 2021, suggests that timely identification of biomarkers of COVID-19 disease severity and mortality would help to provide targeted intervention and patient management. Moreover, many organizations have launched biomarker products to detect and diagnose COVID-19. In November 2020, blinkTEST, a handheld biosensor device that can detect COVID-19 and other disease biomarkers in saliva, will be released by Blink Science, new biotechnology and medical device firm. The stress of awaiting test results can be detrimental to one's health and the global economy. Most current point-of-care (POC) testing devices and those that have received Emergency Use Authorization (EUA) provide results in more than 20-30 minutes.
Furthermore, the high prevalence of cancer and cardiac problems and biomarker advancements are the major factors attributed to biomarker market drivers. The spike in cancer cases globally increased the uses with advances in technology. There were 18 million cases worldwide, according to the WCRF (World Cancer Research Fund International). In addition, governments and pharmaceutical companies are concerned about the global burden of cancer prevention and cure.
According to the World Health Organization, each year, an estimated 17.9 million people die due to cardiovascular diseases worldwide. This represents 35% of global deaths. Moreover, heart attacks and stroke account for 85 percent of all deaths related to cardiovascular disease. Ischemic heart disease (IHD) is also a leading cause of death worldwide, according to an article published in the Cureus Journal of Medical Science in July 2020. Ischemic heart disease affects around 126 million individuals (1,655 per 100,000) globally, approximately 1.72% of the world’s population. The global prevalence of ischemic heart disease is expected to exceed 1,845 per 100,000 by 2030. Also, the burden of cancer continues to grow globally, exerting tremendous physical, emotional, and financial strain on individuals, families, communities, and health systems; according to the Global Cancer Observatory (Globocan) 2020, the estimated prevalent cancer cases all over the globe in 2020 account for 15,545,712. Out of which Asia has 6,108,288 of the general issues, Europe accounts for 3,455,761; North America has 2,166,628, Latin America and the Caribbean has 1,023,898, and Africa has 4.5% 615,015 of the total prevalent cases.
Thus, with the increasing prevalence of life-threatening diseases, the biomarker market is expected to show lucrative growth over the forecast period.
Key Market Trends
Cancer Biomarkers are Expected to Dominate the Market
The rising incidence of different types of cancers is expected to boost demand. For instance, according to Globocan 2020, 1,414,259 new prostate cancer cases were detected in 2020. The high incidence of this cancer type is increasing the demand for biomarkers. One of the most common biomarkers for prostate cancer is prostate-specific antigen (PSA). The PSA test, which detects abnormally high blood levels of PSA, has been used for decades to screen for prostate cancer and potentially diagnose it early.
Additionally, according to Globocan 2020, 2,261,419 new breast cancer cases were detected in 2020. Breast cancer biomarkers, such as estrogen receptor (ER), progesterone receptor, and HER2, are available to see this type of cancer. However, additional tools are required to facilitate the clinical decision-making processes, especially for the optimal treatment of early hormone receptor-positive breast cancer. Some emerging biomarkers include Ki67, Cyclin E, Cyclin D1, and ERβ. The rise in the number of breast cancer cases across the world is expected to boost the demand for biomarkers for its fast detection.
Many companies are involved in the launch of new tests or programs for cancer detection by using biomarkers. For instance, in April 2021, Amgen launched its biomarker assist program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) access biomarker testing. Through this program, eligible patients can save on biomarker testing. Initiatives such as these can boost the market growth.
Additionally, in December 2020, Personalis, Inc. launched its proprietary Neoantigen Presentation Score (NEOPS), a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines analysis from Personalis’ tumor neoantigen prediction tool SHERPA with mechanisms of immune evasion to predict response to cancer therapy better. This is expected to boost the market growth.
Furthermore, the government and pharmaceutical companies are spending a lot on the advancement in the therapy, which eventually leads to the growth of the biomarker market globally. Introducing new cancer biomarkers will increase the market size of biomarkers in the forecast period. Breast and lung cancer dominate the cancer biomarker market, and these cases will increase in the coming years. Thus, the biomarker revenue will also rise in the forecast period.
North America will Dominate the Market in the Forecast Period
North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. The number of USFDA-approved drug labels containing information on molecular biomarkers has increased dramatically over the last decade.
Moreover, the increasing burden of chronic diseases in the United States generates the demand for biomarkers. According to the National Center for Chronic Disease Prevention and Health Promotion’s Article titled Chronic Diseases in America, updated in January 2021, 6 out of the ten adults in the United States have a chronic disease, and 4 in the ten adults have two or more chronic conditions. The biomarker is used for the early diagnosis and treatment of chronic diseases.
Also, the government is focusing on research and the development of biomarkers. For instance, the National Institute of Neurological Disorders and Stroke’s Article titled ‘focus on Biomarker Research,’ updated in July 2021, the NINDS Biomarker Program supports rigorous biomarker development and validation to improve the quality and efficiency of neurotherapeutic clinical research.
Also, according to the Global Cancer Observatory (Globocan) 2020, the United States has the second largest number of prevalent cases of cancer in the world. The real prevalent issues of all ages account for 1,932,997 in 2020. As biomarkers have broad applications in therapy for the diagnosis and treatment of cancer, the demand for them is expected to increase in the country.
The number of products and programs launched by the market players also drives the market's growth in the region. For instance, in April 2021, Amgen launched the Biomarker Assist program to improve the accessibility of biomarker testing for metastatic (stage IV) non-small cell lung cancer (NSCLC) patients. Biomarker testing at the time of diagnosis is an essential first step in ensuring that patients receive the best treatment possible. The eligible patient can save money on biomarker testing with the help of Biomarker Assist.
Thus, for the reasons above, the biomarker market is expected to show lucrative growth in the North American region over the forecast period.
Competitive Landscape
The biomarker market is moderately competitive. The majority of the market share is possessed by Abbott Laboratories Inc., Johnson & Johnson, Roche Diagnostics, Bio-Rad Laboratories, Epigenomics AG, and Qiagen. The growth of this market majorly depends on the advancement in technology and investment in R&D. Today, most pharmaceutical companies are investing in R&D, and governments are also spending a considerable sum of money on the progress of technology.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Quanterix (Aushon Biosystem)
- Bio Rad Laboratories
- Epigenomics AG
- Agilent Technology
- Johnson & Johnson
- Qiagen NV
- Roche Diagnostics
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc
- BioMerieux SA (Astute Medical)
- Zeus scientific
- Myriad genetics
Methodology
LOADING...
